To include your compound in the COVID-19 Resource Center, submit it here.

Portola soars after FDA approves anticoagulant Bevyxxa

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) jumped $17.81 (47%) to $56.06 on Friday after FDA approved Bevyxxa betrixaban to prevent venous

Read the full 198 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE